In Vitro Toxicology Assays Patents: Who Leads, Where the Gaps Are 2026
In Vitro Toxicology Assays: Patents, Leading Filers and Where Claim Space Remains Open
Concentrated at the top. The ranked leader alone accounts for 276 records, and the top 5 assignees combined hold 36.3% of all 1,479 records in scope. Filings hit their peak so far in 2017 at 137, then settled into a lower band. The 2021-to-2024 window — the most recent stretch that can be treated as complete — held flat at 55 filings in both years, a 0% change, indicating a mature but not shrinking filing base rather than a field in retreat.
- 1NEUROGEN CORP276
- 2WYETH LLC99
- 3MADRIGAL PHARMACEUTICALS INC56
- 4BRISTOL MYERS SQUIBB CO55
- 5JANSSEN BIOTECH INC51
See the full in vitro toxicology assays analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on in vitro toxicology assay patents
Who holds the most patents on in vitro toxicology assays?
Ownership is concentrated at the top: the leading assignee alone holds 276 of the 1,479 records in scope, and the top 5 assignees combined account for 36.3% of all records. Below that leader, holdings drop off steeply — fifth place holds 51 records and tenth place 34 — before spreading into a long tail of smaller filers, including universities and contract testing labs. This structure means a single organisation’s portfolio decisions can materially shift the competitive picture, while the rest of the field is fragmented.
Is patent filing for in vitro toxicology assays growing or slowing?
Filings peaked at 137 in 2017 and have since settled lower, holding flat at 55 filings in both 2021 and 2024 — a 0% change over that span. That flat reading is the most reliable recent signal because publication lags filing by roughly 18 months, which means 2025 and 2026 counts are still filling in and should not be read as a real decline. Overall, the field looks mature and steady rather than expanding or contracting sharply.
What patent classes cover in vitro toxicology assay technology?
The dominant classes are A61K (medicinal preparations, 64.2% of the 1,479 records), A61P (therapeutic activity of compounds, 43.4%) and C07D (heterocyclic compounds, 36.5%), reflecting that most filings protect the compounds being screened. Classes tied more directly to the assay method itself, such as G01N (material analysis and testing) at 9.4% and C12Q (enzyme/DNA-based testing) at 6.0%, are comparatively small. Because a single record can carry multiple IPC classes, these shares add up to more than 100% and should not be summed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on In Vitro Toxicology Assays covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.